Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to metastasis ( first projected in the 1896 by Thomas Ashworth, an Australian pathologist, ) and the presence of cfDNA report in human plasma by Mandel and Metals in 1948, liquid biopsy were totally ignored till 1977. In 1977, researchers made the novel observation that cancer patients carried cell-free DNA in their peripheral blood which was Initial progress on further of liquid biopsy. Without a doubt, significant progress was not made until recent years with the advent of Next Generation Sequencing (NGS) technology, which significantly improved the sensitivity and specificity of ctDNA detection. Interestingly, research in this field of liquid biopsy has entered a “golden age” in which the huge potential of liquid biopsy main components including CTCs, cfDNA and exosomes make tumor diagnosis and treatment much clearer than before. Liquid biopsy tests are fast traction as a viable substitute to traditional diagnostic tests for cancer. It has the potential to facilitate detect cancer at earlier stages, present a less-expensive and less-invasive way to monitor patients throughout treatment, and can help doctors make better decisions about which drugs are the best fit for personal patients.
https://lupinepublishers.com/cancer-journal/fulltext/main-components-of-liquid-biopsy-are-greater-than-it-seems.ID.000102.php
https://lupinepublishers.com/cancer-journal/abstracts/main-components-of-liquid-biopsy-are-greater-than-it-seems.ID.000102.php
https://lupinepublishers.com/cancer-journal/pdf/OAJOM.MS.ID.000102.pdf
https://lupinepublishers.com/index.php
